Related Experiment Video
Updated: Apr 12, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
Histone deacetylase inhibitors: a review on class-I specific inhibition
Jagannath Behera, Venkatesan Jayaprakash, Barij Nayan Sinha1
1Birla Institute of Technology, Mesra, Ranchi-835215, India. bnsinha@bitmesra.ac.in.
Abstract:
Histone Deacetylase (HDAC) is an established and validated target for the treatment of cancer. It has been attempted to present a comprehensive review on the inhibitors for Class-I Histone Deacetylase enzyme family, reported during the period from 2002 to 2012. This review has summarized the inhibitors, based on their specificity towards different isoforms within this class. Further various recent United State (US) patents and the HDAC inhibitors, used singly or in combination undergoing clinical trial as anticancer agents have been reviewed. Three such inhibitors SAHA, Romidepsin and Belinostat have already been approved by the US-FDA for the treatment of cancer.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Inhibition of Cdk Activity
Inhibition of CDK Activity
Inhibitors of Viral Protein Synthesis
Histone Modification
Histone Modification
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...

